Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer

  • Entrectinib demonstrated a 78 percent (25 out of 32; by
    Investigator) and 69 percent (22 out of 32; by BICR) confirmed
    objective response rate (ORR) based on an interim analysis of patients
    with ROS1 fusion-positive advanced non-small cell lung cancer
  • Entrectinib showed a median duration of response of 28.6 months and
    median progression free survival of 29.6 months, with 53 percent of
    patients remaining on study
  • Compelling central nervous system (CNS) activity observed, with an
    83 percent (5 out of 6; by BICR) confirmed intracranial ORR in
    patients with measurable CNS metastases at presentation
  • Entrectinib was well tolerated, with more than 200 patients treated
    at the recommended phase 2 dose, with mostly Grade 1-2 reversible
    treatment-related adverse events
  • Company to host conference call and webcast on October 18 at 8:00
    a.m. Eastern Time

Inc. (Nasdaq: RXDX), a biotechnology company focused on
precision medicine in oncology, today announced updated results from its
clinical trials, including the STARTRK-2
trial, of entrectinib – an investigational, CNS-active, potent, and
selective tyrosine kinase inhibitor being developed for tumors that
harbor NTRK
fusions or ROS1 fusions.
In this interim analysis, entrectinib demonstrated a 78% confirmed ORR
(by Investigator; 95% CI: 60.0, 90.7) and a 69% confirmed ORR (by
Blinded Independent Central Review, or BICR; 95% CI: 50.0, 83.9) in 32
patients with locally advanced or metastatic non-small cell lung cancer
(NSCLC) that harbored ROS1 fusions. Entrectinib demonstrated
compelling durability in these patients, with a median duration of
response (mDOR) of 28.6 months (by BICR; 95% CI: 6.8, 34.8; median
follow-up of 12.9 months) and a median progression free survival (mPFS)
of 29.6 months (by BICR; 95% CI: 7.7, 36.6; median follow-up of 8.5
months). Of the patients evaluated, 11 had CNS metastases at baseline as
assessed by Investigator, and 83 percent (5 out of 6; by BICR) of the
patients with measurable CNS metastases at presentation had confirmed
intracranial RECIST responses to treatment with entrectinib. The data
were presented today in an oral presentation at the International
Association for the Study of Lung Cancer (IASLC) 18th World Conference
on Lung Cancer (WCLC) in Yokohama, Japan.

“Based on these data, we believe that entrectinib has the potential to
be a best-in-class therapeutic option as a first-line targeted therapy
for patients with ROS1-positive NSCLC,” said Jonathan Lim, M.D.,
chairman and CEO of Ignyta. “The extended duration of response and
progression free survival times observed in these interim data are
particularly compelling, and we believe may be driven by entrectinib’s
CNS activity. Entrectinib was designed to cross the blood-brain barrier,
allowing it to both address preexisting CNS lesions and have the
potential to prevent or delay the onset of metastases to the brain, a
common site of progression, particularly in NSCLC.”

Safety was consistent with previous studies of entrectinib. With over
200 patients treated at the recommended phase 2 dose, most adverse
events (AEs) were Grade 1-2 and reversible, and only 3 percent of
patients discontinued from the study due to treatment-related AEs
(TRAEs). The most common TRAEs were dysgeusia (38%), fatigue (29%),
constipation (23%), dizziness (23%), and increased weight (19%). The
most common Grade 3 TRAEs were increased weight (5%), anemia (4%), and
fatigue (3%). There were no Grade 4 events occurring in greater than one
percent of patients and no Grade 5 TRAEs.

ROS1 fusions occur in approximately two percent of all cases of
NSCLC and, given the propensity for these tumors to metastasize to the
brain, the CNS activity of entrectinib is a critical differentiating
feature of the compound and may be contributing to the impressive
duration and progression free survival it has demonstrated thus far,”
said Myung-Ju Ahn, Professor in the Department of Hematology and
Oncology at the Samsung Medical Center in Seoul Korea and study author.

In addition to these data in ROS1-positive NSCLC, entrectinib has
demonstrated promising preliminary antitumor activity across NTRK-positive
solid tumors, an indication for which entrectinib has received
breakthrough therapy designation (BTD) from the U.S. Food and Drug
Administration (FDA) and PRIME designation from the European Medicines
Agency (EMA). Based on recent guidance from the FDA, the company is on
track for dual NDA submissions in both the NTRK tissue-agnostic
and the ROS1-positive NSCLC indications in 2018.

A conference call and live webcast will be held on October 18,
2017, at 8:00 a.m. Eastern Time to discuss the data presented, as well
as the comprehensive entrectinib program. To participate in the
conference call, please dial 800-946-0716 (U.S.) or 719-325-4934
(international) and provide Conference ID 7994148. To access the live
webcast, go to

About Entrectinib

Entrectinib is an investigational, CNS-active, potent, and selective
small molecule tyrosine kinase inhibitor of the TRK (tropomyosin
receptor kinase) family of tyrosine kinase receptors (TRKA, TRKB and
TRKC) and ROS1 proteins, which is in a Phase 2 clinical study and two
Phase 1 clinical studies in molecularly defined adult patient
populations for the treatment of solid tumors, and a Phase 1/1b clinical
study in pediatric patients with advanced solid tumor malignancies.


STARTRK-2 is an open-label, multicenter, global Phase 2 basket study of
entrectinib for the treatment of patients with locally advanced or
metastatic solid tumors that harbor NTRK1/2/3, ROS1, or ALK gene
rearrangements. The basket design screens patient tumor samples for the
relevant targets to take full advantage of entrectinib’s demonstrated
preliminary clinical activity across a range of different tumor types
and molecular targets.

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer™

At Ignyta, we work tirelessly on behalf of patients with cancer to offer
potentially life-saving, precisely targeted therapeutics (Rx) guided by
diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter
uncharted territory, illuminating the molecular and immunological
drivers of cancer and quickly advancing treatments to address them. This
approach embraces even those patients with rare cancers, who have the
highest unmet need and who may otherwise not have access to effective
treatment options. With our pipeline of potentially first-in-class or
best-in-class precision medicines, we are pursuing the ultimate goal of
not just shrinking tumors, but eradicating cancer relapse and recurrence
in precisely defined patient populations.

For more information, please visit:

About the WCLC

The World Conference on Lung Cancer (WCLC) is the world’s largest
meeting dedicated to lung cancer and other thoracic malignancies,
attracting over 6,000 researchers, physicians and specialists from more
than 100 countries. The goal is to disseminate the latest scientific
achievements; increase awareness, collaboration and understanding of
lung cancer; and to help participants implement the latest developments
across the globe. Organized under the theme of “Synergy to Conquer Lung
Cancer,” the conference will cover a wide range of disciplines and
unveil several research studies and clinical trial results. For more
information, visit

Forward-Looking Statements

This press release contains forward-looking statements about Ignyta as
that term is defined in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other things:
references to the development of and path to potential regulatory
approval of entrectinib and our other product candidates, including
potential differentiating factors; the clinical and/or non-clinical data
or plans underlying entrectinib or any of our other development
programs, the potential for entrectinib to be a best-in-class
therapeutic, and the corporate milestones and timelines associated with
such programs; our ability to design and conduct development activities
for entrectinib and our other development programs; our ability to
obtain regulatory approvals in order to market any of our product
candidates; and our ability to successfully commercialize any approved
products. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with
developing new products or technologies and operating as a development
stage company; Ignyta’s ability to develop, initiate or complete
preclinical studies and clinical trials for, obtain approvals for and
commercialize any of its product candidates; changes in Ignyta’s plans
to develop and commercialize its product candidates; the potential for
final results of the ongoing clinical trials of entrectinib or other
product candidates, or any future clinical trials of entrectinib or
other product candidates, to differ from preliminary or expected
results; Ignyta’s ability to raise any additional funding it will need
to continue to pursue its business and product development plans;
regulatory developments in the United States and foreign countries; our
dependence on third party manufacturers for supply of our product
candidates and any approved products; Ignyta’s ability to obtain and
maintain intellectual property protection for its product candidates;
the risk that orphan drug exclusivity may not effectively protect a
product from competition and that such exclusivity may not be
maintained; the potential for the company to fail to maintain the CAP
accreditation and CLIA certification of its diagnostic laboratory; the
loss of key scientific or management personnel; competition in the
industry in which Ignyta operates; and market conditions. These
forward-looking statements are made as of the date of this press
release, and Ignyta assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ
from those projected in the forward-looking statements. Investors should
consult all of the information set forth herein and should also refer to
the risk factor disclosure set forth in the reports and other documents
the company files with the SEC available at,
including without limitation Ignyta’s Annual Report on Form 10-K for the
year ended December 31, 2016 and subsequent Quarterly Reports on Form


Ignyta, Inc.
Jacob Chacko, M.D.

Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan

  • Poziotinib demonstrates evidence of significant antitumor activity in
    NSCLC patients with EGFR exon 20 insertion mutations, with interim
    data showing an Objective Response Rate of 73%.
  • Evidence of central nervous system (CNS) activity in a patient with
    CNS metastasis and another with leptomeningeal disease (LMD).
  • On October 18th at 8:30 a.m. EDT/5:30 a.m. PDT, the Company
    will hold a conference call with Dr. John Heymach, from The University
    of Texas MD Anderson Cancer Center to discuss the study results.

HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company
with fully integrated commercial and drug development operations with a
primary focus in Hematology and Oncology, announced the oral
presentation of interim data from a Phase 2 clinical study evaluating
poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (NSCLC) by
scientists from the MD Anderson Cancer Center which was presented
in Yokohama, Japan, October 15-18, 2017. The Company will hold a
conference call tomorrow, October 18th, at 8:30 a.m. EDT/5:30
a.m. PDT with Dr. John Heymach, M.D., Ph.D., Chairman, Professor,
and David Bruton Junior Chair in Cancer Research, Department of
Thoracic/Head and Neck Medical Oncology, The University of Texas MD
Anderson Cancer Center, to discuss his study results.

“These data are remarkable for NSCLC patients with exon 20 insertion
mutations,” said John Heymach, M.D., Ph.D., The University of Texas MD
Anderson Cancer Center. “These patients currently have a poor prognosis,
single-digit response rate on first generation tyrosine kinase
inhibitors (TKI’s), and a PFS of about two months. What is truly
noteworthy is that all 11 study patients who received poziotinib at a
16mg daily dose and have reached their first scan, have seen some level
of tumor shrinkage. Interestingly, we have also seen evidence of CNS
activity. Toxicities have included rash, diarrhea, paronychia, and
mucositis consistent with those previously described for poziotinib and
other TKI’s, which led to dose reduction in 55% of the patients. We
believe that poziotinib specifically inhibits EGFR with exon 20
insertion mutations because it overcomes steric hindrance caused by exon
20 insertions, due to its smaller size and flexibility. To date
poziotinib has shown promising results in patients with exon 20
insertion mutations and we are fortunate to be leading the efforts in
the continuing development of this product.”

“We are greatly encouraged with the clinical data emerging from
poziotinib and plan to pursue its clinical development expeditiously and
aggressively,” said Rajesh C. Shrotriya, M.D., Chairman and Chief
Executive Officer of Spectrum Pharmaceuticals. “In the near future, we
plan to discuss the regulatory pathway for poziotinib with the FDA. At
the same time, we are embarking upon an overall strategy for global
clinical development and regulatory filings. With three promising drugs
in late-stage development, Spectrum’s pipeline has never been as
exciting and our prospects never as bright.”

Conference Call

Wednesday, October 18, 2017 @ 8:30
a.m. Eastern/5:30 a.m. Pacific

Domestic: (877) 837-3910, Conference ID# 86093351

International: (973) 796-5077, Conference ID# 86093351

For interested individuals unable to join the call, a replay will be
available from October 18, 2017 @ 11:30 a.m. ET/8:30 a.m.
PT through October 28, 2017, until 11:30 a.m. ET/8:30 a.m. PT.

Domestic Replay Dial-In #: (855) 859-2056, Conference ID# 86093351

International Replay Dial-In #: (404) 537-3406, Conference ID# 86093351

This conference call will also be webcast. Listeners may access the
webcast, which will be available on the investor relations page
of Spectrum Pharmaceuticals’ website: on October
18, 2017, at 8:30 a.m. Eastern/5:30 a.m. Pacific.

About Poziotinib

Poziotinib is a novel, oral pan-HER inhibitor that irreversibly blocks
signaling through the Epidermal Growth Factor Receptor (EGFR, HER)
Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2
(erbB2), and HER4 (erbB4), and importantly, also HER receptor mutations;
this, in turn, leads to the inhibition of the proliferation of tumor
cells that overexpress these receptors. Mutations or
overexpression/amplification of EGFR family receptors have been
associated with a number of different cancers, including non-small-cell
lung cancer (NSCLC), breast cancer, and gastric cancer. Spectrum
received exclusive license to develop, manufacture, and commercialize
worldwide excluding Korea and China from Hanmi Pharmaceuticals.
Poziotinib is currently being investigated by Spectrum and Hanmi in
several mid-stage trials in multiple solid tumor indications.

About the WCLC

The World Conference on Lung Cancer (WCLC) is the world’s largest
meeting dedicated to lung cancer and other thoracic malignancies,
attracting over 6,000 researchers, physicians, and specialists from more
than 100 countries. The goal is to disseminate the latest scientific
achievements; increase awareness, collaboration, and understanding of
lung cancer; and to help participants implement the latest developments
across the globe. Organized under the theme of “Synergy to Conquer Lung
Cancer,” the conference covers a wide range of disciplines and unveils
several research studies and clinical trial results. For more
information, visit

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in Hematology and Oncology. Spectrum currently markets six
hematology/oncology drugs, and has an advanced stage pipeline that has
the potential to transform the Company. Spectrum’s strong track record
for in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase 3
studies. More information on Spectrum is available at

Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management’s current beliefs and
These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future, including
certain company milestones, Spectrum’s ability to identify, acquire,
develop and commercialize a broad and diverse pipeline of late-stage
clinical and commercial products, the timing and results of FDA
decisions, and any statements that relate to the intent, belief, plans
or expectations of Spectrum or its management, or that are not a
statement of historical fact.
Risks that could cause actual
results to differ include the possibility that Spectrum’s existing and
new drug candidates may not prove safe or effective, the possibility
that our existing and new applications to the FDA and other regulatory
agencies may not receive approval in a timely manner or at all, the
possibility that our existing and new drug candidates, if approved, may
not be more effective, safer or more cost efficient than competing
drugs, the possibility that our efforts to acquire or in-license and
develop additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and quality
control and other risks that are described in further detail in the
Company’s reports filed with the Securities and Exchange Commission.
Company does not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in this
press release except as required by law.

registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliate.

REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc.
Any other
trademarks are the property of their respective owners.

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved


Spectrum Pharmaceuticals, Inc.
Shiv Kapoor
Vice President,
Strategic Planning & Investor Relations
(702) 835-6300

Intermountain Healthcare Announces Precision Health Research Endeavors with 10x Genomics

–Linked-Reads will be used to advance precision health and
personalized medicine–

PLEASANTON, Calif. & ST. GEORGE, Utah–(BUSINESS WIRE)–#ASHG17–Intermountain Precision Genomics and 10x Genomics announced today, the
addition of Chromium™ Genome Solution to the Translational Science
Center (TSC). The center currently houses several of the latest
high-throughput next-generation sequencing instruments for large-scale
whole genome sequencing. The announcement comes in conjunction with the
upcoming American Society of Human Genetics (ASHG) Conference, held in
Orlando, FL October 17-21, 2017. The ASHG Annual Meeting provides a
forum for presentation and discussion of cutting-edge science in all
areas of human genetics.

According to Helaman Escobar, Director of Intermountain’s Translational
Science Center, “The instruments in the Translational Science Center
coupled with the technology solutions provided by 10x Genomics support
Intermountain Healthcare’s initiative to advance precision health to
bring personalized medicine from the lab bench to clinical practice and
improve patient’s lives.”

“We are thrilled that Linked-Reads have been selected for this
initiative. Access to long-range sequence information is becoming the
standard for obtaining the most comprehensive understanding of disease,
and we look forward to help enable Intermountain Healthcare to gain
valuable insights that have previously not been possible,” said Serge
Saxonov, CEO of 10x Genomics.

One of the primary goals of the Translational Science Center is to
sequence groups of samples from Intermountain’s extensive BioRepository,
where biopsy specimens have been stored for decades. In reference to the
biobank, Lincoln Nadauld, MD, PhD, stated, “The secrets to how we should
treat our patients in the future are locked away in our samples stored
from patients of the past.”

The Translational Science Center (TSC) will create a pipeline of genomic
information and eventually impact personalized clinical practice. The
TSC will also collaborate with investigators and clinicians inside and
outside the network of Intermountain hospitals and clinics to enable
their research initiatives.

About 10x Genomics

10x Genomics is changing the definition of sequencing by providing an
innovative genomics platform that dramatically upgrades the capabilities
of existing sequencing technologies. This is achieved through a
combination of new microfluidic science, chemistry and bioinformatics.
By implementing GemCode™ Technology within the Chromium™ System,
researchers can now, for the first time, find new structural variants,
haplotypes and other valuable genomic information with comprehensive
workflows for Single Cell, V(D)J, Genome, Exome and de novo
Assembly applications that incorporate their pre-existing sequencing

For more information, please visit

About Intermountain Healthcare

Intermountain Healthcare is a not-for-profit system of 22 hospitals, 185
clinics, a Medical Group with about 1,500 employed physicians and
advanced practitioners, a health plan group called SelectHealth, and
other medical services. Intermountain is widely recognized as a leader
in transforming healthcare through high quality and sustainable costs.
For more information about Intermountain Healthcare, visit

About Intermountain Precision Genomics Translational Science Center

Intermountain Precision Genomics announced the creation of a
Translational Science Center (TSC) within the Intermountain Healthcare
system in January 2017. The center will house several of the latest
high-throughput next-generation sequencing instruments for large-scale
whole genome sequencing. This initiative comes as Intermountain’s next
step to bring personalized medicine from the lab bench to clinical
practice and improve patient’s lives.

For more information about Precision Genomics, please visit:,
join the dialog on Facebook (Intermountain
Cancer Centers), or call (435) 251-5780.


10x Genomics
Sara Agee, (510) 590-6997
Terri Draper, (435) 251-2108

Ryan Ferrell, (312) 506-5202

Pure Communications
Matt Clawson, (949) 370-8500

RenovaCare, Inc. Closes Registered Direct Offering and Concurrent Private Placement

NEW YORK & PITTSBURGH & BERLIN–(BUSINESS WIRE)–RenovaCare, Inc., (OTCQB:RCAR), developer of the SkinGun™ and CellMist™
System for isolating and spraying a patient’s own stem cells onto burns
and wounds for rapid self-healing, today announced that it has entered
into definitive agreements with investors to purchase an aggregate of
approximately 915,000 shares of common stock in a registered direct
offering and common stock purchase warrants in a concurrent private

The offerings are expected to yield total gross proceeds of
approximately $2.3 million before deducting estimated offering expenses.
The Company intends to use the net proceeds from the offering for
working capital and other general corporate purposes. The closing of the
offerings took place on October 16, 2017, subject to the satisfaction of
customary closing conditions. The offerings were conducted directly by
the Company without the assistance of placement agents.

This registered offering is being made pursuant to an effective shelf
registration statement (No. 333-217499) previously filed with and
declared effective by the U.S. Securities and Exchange Commission (the “SEC”).
A prospectus supplement and accompanying base prospectus describing the
terms of the offering will be filed with the SEC and will be available
on the SEC’s website located at
Copies of the prospectus supplement and the accompanying base prospectus
relating to this offering may be obtained, when available, from the
Company via telephone at (888) 398-0202 or email:

The unregistered warrants were offered pursuant to the exemption from
registration afforded by Section 4(a)(2) under the Securities Act of
1933, as amended (the “Act”), and Regulations D and S promulgated
thereunder. Such warrants and the common shares issuable upon exercise
of such warrants have not been registered under the Act, and may not be
offered or sold in the United States absent registration with the SEC or
an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

About RenovaCare

RenovaCare, Inc. is developing first-of-its-kind autologous
(self-donated) stem cell therapies for the regeneration of human organs.
Its initial product under development targets the body’s largest organ,
the skin. The company’s flagship technology, the CellMist™ System, uses
its patented SkinGun™ to spray a liquid suspension of a patient’s stem
cells – the CellMist™ Solution – onto wounds. RenovaCare is developing
its CellMist™ System as a promising new alternative for patients
suffering from burns, chronic and acute wounds, and scars. In the US
alone, this $45 billion market is greater than the spending on
high-blood pressure management, cholesterol treatments, and back pain

For additional information, please call Drew Danielson at: 888-398-0202
or visit:

To receive future press releases via email, please visit:

Follow us on Twitter
or follow us on Facebook

For answers to frequently asked questions, please visit our FAQ’s page:

Social Media Disclaimer Investors and others should note that we
announce material financial information to our investors using SEC
filings and press releases. We use our website and social media to
communicate with our subscribers, shareholders, and the public about the
company, RenovaCare, Inc. development, and other corporate matters that
are in the public domain. At this time, the company will not post
information on social media that could be deemed to be material
information unless that information was distributed to public
distribution channels first. We encourage investors, the media, and
others interested in the company to review the information we post on
the company’s website and the social media channels listed below:

• Facebook
• Twitter
* This list may be updated from time to

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of
an offer for the purchase or sale of any securities. This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about future
events. Although RenovaCare, Inc. (the “Company”) believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have been
correct. Forward-looking statements, which involve assumptions and
describe our future plans, strategies, and expectations, are generally
identifiable by use of the words “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or
the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements are
subject to numerous factors and uncertainties, including but not limited
to: the timing and success of clinical and preclinical studies of
product candidates, the potential timing and success of the Company’s
product programs through their individual product development and
regulatory approval processes, adverse economic conditions, intense
competition, lack of meaningful research results, entry of new
competitors and products, inadequate capital, unexpected costs and
operating deficits, increases in general and administrative costs,
termination of contracts or agreements, obsolescence of the Company’s
technologies, technical problems with the Company’s research, price
increases for supplies and components, litigation and administrative
proceedings involving the Company, the possible acquisition of new
businesses or technologies that result in operating losses or that do
not perform as anticipated, unanticipated losses, the possible
fluctuation and volatility of the Company’s operating results, financial
condition and stock price, losses incurred in litigating and settling
cases, dilution in the Company’s ownership of its business, adverse
publicity and news coverage, inability to carry out research,
development and commercialization plans, loss or retirement of key
executives and research scientists, and other risks. There can be no
assurance that further research and development will validate and
support the results of our preliminary research and studies. Further,
there can be no assurance that the necessary regulatory approvals will
be obtained or that the Company will be able to develop commercially
viable products on the basis of its technologies. In addition, other
factors that could cause actual results to differ materially are
discussed in the Company’s most recent Form 10-Q and Form 10-K filings
with the Securities and Exchange Commission. These reports and filings
may be inspected and copied at the Public Reference Room maintained by
the U.S. Securities & Exchange Commission at 100 F Street, N.E.,
Washington, D.C. 20549. You can obtain information about operation of
the Public Reference Room by calling the U.S. Securities & Exchange
Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission
also maintains an Internet site that contains reports, proxy and
information statements, and other information regarding issuers that
file electronically with the U.S. Securities & Exchange Commission at
The Company undertakes no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.


RenovaCare Inc.
Drew Danielson, 888-398-0202

‘Keeping the Promise—AHF 30 Years’

Documentary film screening Thursday, October 19th
at Hollywood’s historic Arclight Cinerama Dome Theater to mark AIDS
Healthcare Foundation’s 30
th Anniversary in

AHF, the largest global AIDS organization—which now provides HIV/AIDS
care and services, including antiretroviral treatment, to more than
821,000 people in 38 countries—will mark its anniversary throughout the
end of 2017 with global events, including screenings of the film
, ‘Keeping
the Promise—AHF 30 Years.’

is honored to announce a significant milestone: this year marks the
observation and celebration of AHF’s 30th anniversary, an
accomplishment that now includes providing HIV/AIDS prevention, care and
services—including lifesaving antiretroviral treatment, to more than
821,000 people in 38 countries in the US, Europe, Africa, Latin
America/Caribbean and Asia.

As part of its 30th anniversary, AHF will mark the
achievement throughout the remainder of 2017 with a series of global
events and activities, including screenings of the new one-hour
documentary, ‘Keeping the Promise—AHF 30 Years.’ Through
interviews with key AHF stakeholders from over the years coupled with
archival video footage culled from AHF’s 30 years of advocacy, care and
activism, ‘Keeping the Promise—AHF 30 Years’ tells a compelling
story of AHF’s history while offering a glimpse of, and road map to its


Screening & Celebration/Reception


Thursday, October 19, 2017

• 6:00 PM reception

• 7:00 PM film screening (one hour) with brief 30th
Anniversary Ceremony to follow


Arclight Theater Hollywood, 6360 W. Sunset Blvd, Los
Angeles CA 90028


Ged Kenslea, AHF, 323.791.5526 mobile

Christopher Johnson, AHF 310.880.9913 mobile


Staff and public screenings of the film start in October and will
continue through the end of the year as the observation of World AIDS
Day approaches (observed each year on December 1st) when AHF
will also host a number of World AIDS Day/AHF 30th
Anniversary concerts and community activations around the globe. ‘Keeping
the Promise—AHF 30 Years’
was made by Foxhound
and will also be subtitled in at least nine (9)
additional languages: Spanish, French, Chinese, Portuguese, Nepali,
Khmer, Russian, Ukrainian and Hindi—languages spoken in many of the
countries and regions where AHF currently operates and provides care and

Founded in 1987 first as the AIDS Hospice Committee and later the AIDS
Hospice Foundation, AHF’s earliest days were a heartfelt, grassroots
community effort to provide end-of-life hospice care to people with AIDS
in Los Angeles, California at a time in the mid-1980s before lifesaving
drug treatment was available for people with HIV/AIDS. Thirty years
later, AHF has now grown to become the largest global AIDS organization.

“On this occasion of the 30th anniversary of the founding of
AHF, I want to thank our board of directors, our staff of 5,600, our
821,000 patients and the community of supporters we have around the
country and the world. Everything we have accomplished is because of
your dedication. AHF stands as living proof that the world can be
changed for the better if you are willing to work hard and dedicate
yourself to a mission,” said Michael Weinstein, AHF’s President
and founder. “I really wish that Chris Brownlie, my dear friend and
co-founder of AHF, could be alive today to see what his voice inspired.
While we celebrate this milestone, we recognize that there is still so
much more work to be done before we defeat AIDS once and for all time.”

“Congratulations to all of the AHF staff, Board members, volunteers,
partners and our patients for contributing your best to help AHF meet
this remarkable thirty-year milestone with over 821,000 patients now in
AHF’s care somewhere in the world,” said Cynthia Davis, MPH,
Assistant Professor, College of Medicine, Charles R. Drew University of
Medicine and Science and Chair of AHF’s Board of Directors. “On behalf
of the Board, we are honored and proud of the work done—and to work
alongside you—in the fight against AIDS each day. Members of the Board
also look forward to celebrating this milestone with many of you at
these events, celebrations and film screenings at AHF locations around
the corner and around the globe, as well as during our upcoming ‘Keep
the Promise’ World AIDS Day concerts and community events. Again,
heartfelt congratulations and thanks to all those involved in this
remarkable AHF accomplishment.”

AHF provides medical care and services at over 435 global clinics in 37
other countries outside to U.S. including:

THE AMERICAS—11 countries, including: Argentina,
, Guatemala,
and Peru
(as well as the previously cited United

AFRICA—11 countries, including: Ethiopia,
, South
, Swaziland,
and Zambia.

ASIA—9 countries, including: Cambodia,
and Vietnam.

EUROPE—7 countries, including: Estonia,
and Ukraine.

In addition, AHF operates 48 free HIV/AIDS healthcare centers in 14
states and the District of Columbia in the U.S. (California, Florida,
Georgia, Illinois, Indiana, Louisiana, Maryland, Mississippi, Nevada,
New York, Ohio, South Carolina, Texas, Washington
[state] and Washington,

Today, in addition to its clinics and treatment centers, AHF also
operates a chain of 46 AHF
outlets in 11 states and runs managed care and disease
management programs for people with AIDS or HIV in Florida and
California under AHF’s Positive
umbrella. Through AHF’s Public Health Division, AHF
operates one of the largest community-based free
HIV testing
programs in the US (176,950 free tests in the U.S. in
2016). In addition, nearly five million free HIV tests were done
globally by AHF in 2016 (4,876,600 tests). AHF also operates 21 Wellness
Centers in eight states (and four additional Wellness Centers in two
other countries) and also operates two AHF Dental Clinics in South
Florida and Southern California. The AHF
Research Division
has nearly 23 years of experience with
antiretroviral (ARV) studies. AHF also operates the award-winning chain
of ‘Out
of the Closet
’ thrift stores—currently 21 outlets in seven states in
the U.S., many of which are free HIV testing sites as well.

AIDS Healthcare Foundation (AHF), the largest global AIDS
organization, currently provides medical care and/or services to over
817,000 individuals in 38 countries worldwide in the US, Africa, Latin
America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn
more about AHF, please visit our website:,
find us on Facebook:
and follow us on Twitter: @aidshealthcare.


AIDS Healthcare Foundation
Ged Kenslea, Senior Director,
+1.323.308.1833 work
+1.323.791.5526 mobile

Most Energy Efficient Performance in Ultra-Low Temperature Technology on Exhibit at I2SL, Boston

WOOD DALE, Ill.–(BUSINESS WIRE)–#I2SL–Panasonic Healthcare Corporation of North America is exhibiting the
ENERGY STAR® Certified, 25.7 cu.ft. -86°C ultra-low temperature freezer
at the I2SL Annual Conference, October 16-18, 2017, Boston Marriott
Copley Place, exhibit booth 24. Marketed as the VIP® ECO Model
MDF-DU702VH-PA, the freezer is designed and independently verified to
deliver the industry’s most energy efficient performance.

Panasonic Healthcare claims are based on third-party testing at time of
submission, using an air-cooled refrigeration system with standard
features. Test results are available on the ENERGY STAR website at,
Certification Number 4787624501.

Successful development of the VIP ECO is based on long-awaited
guidelines from the Environmental Protection Agency (EPA) setting forth
criteria upon which ENERGY STAR Certification is written. In a summary
of key metrics critical to facility managers focused on total life-cycle
costs and long-term energy savings, the VIP ECO outperforms competitive
freezers in areas of power consumption, interior temperature uniformity
and temperature recovery after door openings.

VIP ECO performance yields an ENERGY STAR composite power consumption
rating ~ -75°C of 7.87 kWh at 6x door openings per day, and 7.30
at zero door openings per day.

Summary Results, Independent Testing, Factory Testing for BTU/Hour,
24°C Ambient, Air-Cooled System

Energy Consumption
-70°C   6.19 kWh zero openings, 6.72 kWh six openings
-80°C 8.40 kWh zero openings, 9.0 kWh six openings
Interior Temperature Uniformity Average
-70°C ~1.95°C
-80°C ~2.67°C
Recovery after Door Opening
-70°C 8 minutes
-80°C 8 minutes
BTU/Hour, Factory Tests
-70°C 810
-80°C 1109

According to Steven Lynum, Senior Vice President, Panasonic Healthcare
Corporation of America, the effort to bring transparency into the
ultra-low temperature freezer market has taken years to emerge and
continues to evolve.

“We thank the EPA for allowing us to play a part since the beginning of
the criteria development,” says Lynum. “The industry will now be
accountable for not only performance claims, but also the impact on
reliability and true sustainability. The Panasonic Healthcare variable
speed cascade refrigeration platform with natural refrigerants now
presents sustainable solutions to a market in critical need for
performance and dependability in addition to energy efficiency. Our
customers have always known that our freezers perform exactly as
advertised; and now we advertise it as the world’s most energy efficient
ULT as per the EPA’s current website listing. We will always view this
commitment to the customer as a social responsibility.”

In addition to the VIP ECO, selected Panasonic ENERGY STAR Certified
high performance undercounter refrigerators and freezers are among the
highest rated in their class for energy efficiency in lab grade storage.

Panasonic Healthcare Corporation of North America is a subsidiary of
Panasonic Healthcare Holdings, Co. Ltd., Tokyo, Japan, and offers
laboratory equipment and services to biopharmaceutical, life sciences,
academic, healthcare and government markets. For information call
Panasonic Healthcare Corporation of North America at 800-858-8442 or


Panasonic Healthcare
Katie Hardy, 630-694-8265

IntriCon to Announce 2017 Third-Quarter Results on Monday, November 6

Company to Hold Investor Conference Call at 4:00 p.m. CT

ARDEN HILLS, Minn.–(BUSINESS WIRE)–IntriCon Corporation (NASDAQ: IIN), a designer, developer,
manufacturer and distributor of body-worn devices, today announced that
it will release its 2017 third-quarter results on Monday, November 6,
2017, at market close.

Following the release, the company will hold an investment community
conference call on the same day, beginning at 4:00 p.m. CT. Mark Gorder,
president and chief executive officer, and Scott Longval, chief
financial officer, will review the company’s financial performance and
discuss its strategies. To join the conference call, dial:
1-800-289-0548 and provide the conference ID number 5232505 to the

A replay of the conference call will be available three hours after the
call ends through 7:00 p.m. CT on Monday, November 20, 2017. To access
the replay, dial 1-888-203-1112 and enter passcode 5232505.

About IntriCon Corporation
Headquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures miniature
and micro-miniature body-worn devices. These advanced products help
medical, healthcare and professional communications companies meet the
rising demand for smaller, more intelligent and better connected
devices. IntriCon has facilities in the United States, Asia and Europe.
The company’s common stock trades under the symbol “IIN” on the NASDAQ
Global Market. For more information about IntriCon, visit


At IntriCon:
Scott Longval, CFO, 651-604-9526
Matt Sullivan, 612-455-1709

BioTime, Inc. Announces Closing of Public Offering and Underwriters’ Full Exercise of Over-Allotment Option

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage
clinical biotechnology company focused on developing and commercializing
products addressing degenerative diseases, today announced the closing
of its previously announced public offering of 9,615,385 shares of
common stock, including 1,442,308 shares sold pursuant to the
underwriters’ exercise in full of their option to purchase additional
shares. The offering price to the public was $2.60 per share, and gross
proceeds from the offering, before underwriting discounts and
commissions and offering expenses, were approximately $28.8 million.

BioTime intends to use the net proceeds from this offering for general
corporate purposes, including, without limitation, to fund clinical
trials, research and development activities and for general working

Raymond James & Associates, Inc. acted as the sole book-running manager
for the offering. Ladenburg Thalmann & Co. Inc., Chardan and LifeSci
Capital LLC acted as co-managers. Lake Street Capital Markets acted as a
financial advisor for the offering.

A registration statement on Form S-3 (File No. 333-217182) was
previously filed with the Securities and Exchange Commission (the “SEC”)
and became effective on May 5, 2017. A final prospectus supplement
relating to the offering has been filed with the SEC and is available on
the SEC’s website, located at
Copies of the prospectus supplement and accompanying prospectus relating
to the offering may be obtained from Raymond James & Associates, Inc.,
Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg,
Florida 33716, or by telephone at (800) 248-8863, or e-mail at

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

About BioTime, Inc.

BioTime is a late stage clinical biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting three
primary sectors: aesthetics, ophthalmology and cell and drug delivery.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that statements in this
press release regarding the use of the proceeds from the offering
constitute forward-looking statements that involve risks and
uncertainties, including, without limitation, risks and uncertainties
related to management’s discretion with respect to the use of proceeds
from this offering. Additional information on risks facing BioTime, its
subsidiaries and its affiliates can be found in the “Risk Factors”
section of its Annual Reports on Form 10-K and Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission (the “SEC”) and
in the prospectus supplement related to the proposed offering filed with
the SEC on October 13, 2017 (copies of which may be obtained at
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.


Investor Contact:
David Nakasone, 510-871-4188

JQA Partners, Inc.
Jules Abraham, 917-885-7378

As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada

Ethically challenged drug company has made billions off the drug
since its initial FDA approval while it simultaneously sought to
‘evergreen’ and manipulate patent extension process

Healthcare Foundation (AHF)
, the largest global AIDS organization
and a vocal critic of runaway drug pricing and drug profiteering, today
called on Gilead
Sciences, Inc.
to reduce the price of its tenofovir-based drug
regimens—including Truvada—by as much as 90%.

The California drug company has made billions off of sales of its
tenofovir-based drugs since the FDA first approved Gilead’s tenofovir
disoproxil fumarate (TDF), branded as Viread, on October 26,
2001. The patent is set to expire on December 15, 2017, with the patent
on a pediatric version of the drug set to expire in early 2018.

Since FDA approval of the drug in 2001, the TDF formulation of tenofovir
has become a cornerstone of other big money Gilead combination HIV/AIDS
treatment therapies beyond Viread including:

  • Atripla (efavirenz + tenofovir disoproxil fumarate +
    emtricitabine—made in partnership with Bristol-Myers Squibb), Average
    Wholesale Price1(AWP):
    $2,869.86 USD per patient-per month / $34,438.32 USD yearly
  • Complera (rilpivirine + tenofovir disoproxil fumarate +
    emtricitabine—made in partnership with Janssen Theraputics), AWP:
    $2,815.04 USD per month / $33,780.48 USD yearly
  • Stribild, the four-drug-in-one tablet (elvitegravir +
    cobicistat + tenofovir disoproxil fumarate + emtricitabine), AWP:
    $3,244.76 USD per month / $38,973.12 USD yearly
  • Truvada (tenofovir disoproxil fumarate + emtricitabine),
    Gilead’s blockbuster HIV/AIDS treatment that is also the medication
    component used for pre-exposure prophylaxis (PrEP) to prevent HIV
    acquisition. AWP: $1,759.73 USD per month / $21,116.76 USD yearly; and
  • Viread (tenofovir disoproxil fumarate or ‘TDF previously cited
    above’), AWP: $1,197.32 USD per month / $14,367.84 USD yearly.

“Gilead has made untold billions off of tenofovir in its various
treatment combinations since its introduction in 2001. More recently, it
tried to extend its patent monopoly on tenofovir in order to maintain
enormous profit margins on the drug. But the tenofovir patent expires in
just a few short weeks, meaning the generic market for the drug will
open widely,” said Michael Weinstein, President of AHF. “As a
result, with the patent ending and generic versions on the horizon, we
call on Gilead for an immediate ninety-percent reduction across the
board on the price of all tenofovir-based drugs—including on Truvada, as
well as combination therapies using tenofovir that Gilead makes in
partnership with companies like BMS and Janssen.”

In February 2016, AHF filed a lawsuit against Gilead over its
manipulation of the patent system in order to derail competition to its
HIV medicines. As reported at the time by Ed Silverman on the health
news service, STAT,
“At issue is tenofovir, or TDF, which is a cornerstone of the
combination HIV treatments that Gilead sells. The patent on the TDF
compound expires in December 2017 and Gilead hopes to replace it with a
modified version known as TAF. The patent on TAF doesn’t expire until
May 2022, and the prospect of nearly five more years of sales without
generic competition is extremely valuable.”

He also noted, “There is another important difference between the two
compounds — TAF is more potent and causes fewer side effects, notably
bone damage and kidney toxicity.”

In 2014 in anticipation of Viread’s upcoming patent expiration, Gilead
pulled a much more efficacious 30mg lower dose version of Viread off its
development shelf and instead began the evergreening process by filing
its first New Drug Application (NDA) for the modified Viread molecule,
tenofovir alafenamide, or TAF (later branded Vemlidy).

It should be noted that Teva, an Israeli multinational pharmaceutical
company and generic drug manufacturer, is allowed to begin production of
a generic version of Viread as of December 15, 2017, resulting from its
litigation against Gilead. Truvada, which contains the older version of
Viread combined with a second Gilead drug called Emtriva, can also go
generic as of December 2017.

What is most telling about Gilead’s corporate conscience—or lack
thereof—is that after many years of incredible successes, this newer TAF
version of Viread, which has a significantly better adverse event
profile (particularly regarding renal side effects that impact African
Americans much more) was reportedly left on the shelf post-development
by Gilead Sciences for years. The reason for doing so is obvious: to
maximize profits via the evergreening process by waiting until just the
right time to begin filing new drug applications for all previously
approved combination therapies. This effectively extends patent life of
Gilead’s drug portfolio and greatly enhances the profit margins for

“Gilead shamelessly used every tactic in the pharma greed book to try
and evergreen its HIV portfolio using a scientific tweak to the
tenofovir molecule to try and reset the patent clock and add another 17
years to the patent cycle. Gilead also increases prices on its HIV/AIDS
and hepatitis drug portfolio consistently—and well above the consumer
price index. Well, tick-tock Gilead, the clock stops on tenofovir on
December 15th. We urge you to immediately cut the price of
all tenofovir-based regimens by ninety-percent,” added Weinstein.

AIDS Healthcare Foundation (AHF), the largest global AIDS
organization, currently provides medical care and/or services to more
than 810,000 individuals in 38 countries worldwide in the US, Africa,
Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To
learn more about AHF, please visit our website:,
find us on Facebook:
and follow us on Twitter: @aidshealthcare.

1 The Average Wholesale Price (AWP) is the
average price that retailers and others are reportedly paying for a
particular drug. The AWP is reported by the manufacturers and compiled
by independent publishers, the data of which is used by governments,
insurance companies, and others to determine the reimbursement and
retail prices of prescription drugs. Source:
April 24, 2017


Ged Kenslea, Senior Director, Communications
(323) 308-1833
Mobile: (323) 791-5526

Walgreens to Establish New Technology Center of Excellence in the Sullivan Center

Company to Double Number of Employees in Downtown Chicago Office with
300 Additional Positions

DEERFIELD, Ill.–(BUSINESS WIRE)–Walgreens today announced with Chicago Mayor Rahm Emanuel that it will
bring approximately 300 technology positions to its current downtown
Chicago office in the Sullivan Center to establish a new technology
center of excellence. Through a combination of new hires and relocations
from its Deerfield, Ill., support office, Walgreens will double its
number of employees working at the Sullivan Center, located at 36 S.
Wabash Ave.

Walgreens is currently building out its space in the Sullivan Center to
host the new center of excellence, which will host much of the company’s
retail pharmacy technology team along with the digital, mobile and
e-commerce technology teams that currently work there.

“We are excited to bring more technology jobs to the City of Chicago and
establish a technology center of excellence that will focus on
delivering state-of-the-art systems to our more than 8,000 drugstores
nationwide,” said Alex Gourlay, president of Walgreens. “Chicago is
where Walgreens began as a single drugstore in 1901, and expanding our
downtown presence will help us retain and attract the best talent to
continue developing our digital and technology capabilities.”

Walgreens already employs more than 3,500 people in the City of Chicago,
where it operates 136 drugstores.

“Chicago and Walgreens have a long and shared history of innovation and
ingenuity,” Mayor Emanuel said. “That history makes Chicago the perfect
city for Walgreens to locate 300 jobs and make an investment in its

About Walgreens

Walgreens (,
one of the nation’s largest drugstore chains, is included in the Retail
Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA),
the first global pharmacy-led, health and wellbeing enterprise. More
than 10 million customers interact with Walgreens each day in
communities across America, using the most convenient, multichannel
access to consumer goods and services and trusted, cost-effective
pharmacy, health and wellness services and advice. Walgreens operates
8,175 drugstores with a presence in all 50 states, the District of
Columbia, Puerto Rico and the U.S. Virgin Islands, along with its
omnichannel business, Approximately 400 Walgreens stores
offer Healthcare Clinic or other provider retail clinic services.


Phil Caruso